Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor
Kenji Hashimoto
Topics & Concepts
Sigma-1 receptorFluvoxamineDrug repositioningCoronavirusMedicinePharmacologyReceptorVirologyBiologyDrugCoronavirus disease 2019 (COVID-19)DiseaseAgonistInternal medicineInfectious disease (medical specialty)SerotoninFluoxetinePharmacological Receptor Mechanisms and EffectsTryptophan and brain disordersLong-Term Effects of COVID-19